CI vs OFIX: fair value comparison
The Cigna Group and Orthofix Medical Inc. · Updated 2026-10-19
OFIX is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, OFIX currently ranks higher by quality score.
| CI | OFIX | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $282.43 | $9.38 |
| 12-month range | $244.41–$309.18 | $8.64–$16.20 |
| Rank by discount to fair value | #28 of 108 Healthcare | — |
| Rank by quality score | #169 of 301 Healthcare | #168 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CI fair value analysis · OFIX fair value analysis